Adze oncolytic immunotherapies harness immune response mechanisms to enable the patient's body to fight cancers.
Adze oncolytic immunotherapy payloads target immune stimulatory and inhibitory receptors on T, NK, and dendritic cells and macrophages to further amplify the immune response.
The neoantigens released from lysed cancer cells, coupled with recruited and stimulated immune cells, generate in situ systemic cancer vaccine responses, a key goal in immuno-oncology.
ADZ Hexon proteins are designed to evade scavenger receptors in the liver's Kupffer cells. These modifications allow for greater systemic anti-cancer therapy activity.